Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.
Advertisement

Related Content

Gilead Letairis Will Be Available Through LEAP Restricted Distribution Program
Actelion Will Take Novel Sleep Therapy Into Phase III This Year
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
FDA To Review Gilead’s Ambrisentan And Encysive’s Thelin Back-To-Back
Gilead Ramps Up For Ambrisentan; Calls For 75 To 100 Sales Reps
Gilead Submits NDA For Ambrisentan For PAH
Encysive Hits Another Snag With Thelin
Encysive’s Thelin Gets EU Nod Ahead Of U.S.
Encysive Holds Hope For Thelin Despite Receiving Second “Approvable” Letter
Encysive Holds Hope For Thelin Despite Receiving Second “Approvable” Letter

Topics

Advertisement
UsernamePublicRestriction

Register

PS063606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel